+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Sulindac sulfide--induced stimulation of eryptosis



Sulindac sulfide--induced stimulation of eryptosis



Cellular Physiology and Biochemistry 30(4): 1072-1082



Sulindac sulfide, a non-steroidal anti-inflammatory drug (NSAID), stimulates apoptosis of tumor cells and is thus effective against malignancy. In analogy to apoptosis of nucleated cells, erythrocytes may undergo eryptosis, an apoptosis-like suicidal erythrocyte death, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine-exposure at the cell surface. Stimulators of eryptosis include increase of cytosolic Ca(2+)-activity ([Ca(2+)](i)) and ceramide formation. The present study explored, whether sulindac sulfide stimulates eryptosis. [Ca(2+)](i) was estimated from Fluo-3 fluorescence, cell volume from forward scatter, phosphatidylserine-exposure from binding of fluorescent annexin-V, hemolysis from hemoglobin release, and ceramide abundance utilizing fluorescent antibodies. A 48 h exposure to sulindac sulfide (≤ 20 µM) was followed by significant increase of [Ca(2+)](i), enhanced ceramide abundance, decreased forward scatter and increased percentage of annexin-V-binding erythrocytes. Sulindac sulfide triggered slight but significant hemolysis. Removal of extracellular Ca(2+) significantly blunted, but did not abrogate the effect of sulindac sulfide (20 µM) on annexin-V-binding. Sulindac sulfide stimulates the suicidal death of erythrocytes or eryptosis, an effect paralleled by Ca(2+)-entry, ceramide formation, cell shrinkage and phosphatidylserine-exposure.

(PDF emailed within 0-6 h: $19.90)

Accession: 056007878

Download citation: RISBibTeXText

PMID: 23202471

DOI: 10.1159/000341483


Related references

Inhibition of UVB-induced AP-1 activation by sulindac, sulindac sulfide, and sulindac sulfone. Proceedings of the American Association for Cancer Research Annual Meeting (41): 494, March, 2000

Differential targeting of protein kinase B in cell death induced by sulindac and its metabolite sulindac sulfide. International Journal of Oncology 28(6): 1471-1479, 2006

Sulindac and its metabolites sulindac sulfide and sulindac sulfone induce apoptosis in human cervical cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 39: 196, March, 1998

Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines. Toxicology in Vitro 25(5): 1075-1084, 2011

Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites sulindac sulfide and sulindac sulfone on human leu. 2011

Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines. Medical Oncology 29(2): 1161-1172, 2012

Sulindac an sulindac sulfide affect colon adenocarcinoma cells regardless of their p53 and APC genotypes or RER phenotype. Gastroenterology 110(4 SUPPL ): A520, 1996

In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Japanese Journal of Pharmacology 32(5): 833-838, 1982

Sulindac and sulindac sulfide alter the levels of Bcl-2 and Bax proteins in HT-29 colon cancer cells. Gastroenterology 108(4 SUPPL ): A475, 1995

Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1(2): 170-176, 2000

Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia (New York) 1(2): 170-176, June, 1999

Long term exposure to sulindac sulfide , sulindac sulfone and nimesulid which involve different metabolic pathways is safe. Gastroenterology 116(4 PART 2): A373, April, 1999

Sulindac and sulindac sulfide alter the levels of pRb and p53 and the cyclin dependent kinase inhibitor p21 IN HT-29 colon cancer cells. Gastroenterology 108(4 SUPPL ): A475, 1995

Reduction of Sulindac to its active metabolite, sulindac sulfide: assay and role of the methionine sulfoxide reductase system. Biochemical and Biophysical Research Communications 312(4): 1005-1010, 2003

Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic & Clinical Pharmacology & Toxicology 99(4): 294-299, 2006